/Companies

MBQ Pharma

San Juan, US

Find your way into MBQ Pharma

263 people in our graph share verified history with the MBQ Pharma team — schools, employers, funds. One of them is your warm intro.

Desmond Padhiunlockedknows CARLOS A DOMINGUEZ · together at Schering-Plough (overlapped)
×8knows the team · via Schering-Plough
×3knows the team · via University of Puerto Rico

MBQ Pharma develops precision therapeutics that target Rac and CDC42 GTPases for cancer, autoimmune, and fibrotic diseases, with a lead compound (MBQ-167) aimed at preventing and removing metastases. Its lead candidate is in a Phase 1 study, based on IP licensed from the University of Puerto Rico.

Founders & leadership

SD
SURANGANIE DHARMAWARDHANEChief Scientific Officer
CV
CORNELIS VLAARChief Development Officer
CACARLOS A DOMINGUEZ
CARLOS A DOMINGUEZChief Financial OfficerCarlos A Dominguez is a healthcare executive with over 27 years of pharmaceutical industry experience, including leadership roles at Biogen, Probiomed, MSD, Teva, and most recently as General Manager of Synthon Mexico, where he led commercial transformation and market development. He brings expertise in general management, business transformation, commercial strategy, and market access.
JFJOSE F RODRIGUEZ-ORENGO
JOSE F RODRIGUEZ-ORENGOChief Executive OfficerJosé F. Rodríguez-Orengó is Chief Business Officer at MBQ Pharma, which develops precision therapeutics targeting Rac and CDC42 GTPases for cancer and fibrotic diseases. He previously served as a biochemistry professor at the University of Puerto Rico School of Medicine and led clinical research operations at FDI Clinical Research.
FG
FEDERICO GOODSAIDChief Executive Officer
EH
ELIUD HERNANDEZChief Operating Officer

Board

AG
ARTURO GONZALEZBoard of Directors Member
HG
HUMBERTO GUZMANBoard of Directors Member

Reported raises · per SEC filings

Form D private placements

$4.2M disclosed across 5 rounds · 2018–2026

▶$1.5MraisedAug 2026 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • CARLOS A DOMINGUEZExecutive Officer
  • JOSE F RODRIGUEZ-ORENGOExecutive Officer
  • SURANGANIE DHARMAWARDHANEExecutive Officer, Director
  • FEDERICO GOODSAIDExecutive Officer, Director
  • CORNELIS VLAARExecutive Officer, Director
  • ELIUD HERNANDEZExecutive Officer
Amount sold
$1.5M
First sale
Jun 2018
Incorporated
Corporation, Puerto Rico
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$882KraisedAug 2026 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • CARLOS A DOMINGUEZExecutive Officer
  • JOSE F RODRIGUEZ-ORENGOExecutive Officer, Director
  • SURANGANIE DHARMAWARDHANEExecutive Officer
  • FEDERICO GOODSAIDExecutive Officer, Director
  • CORNELIS VLAARExecutive Officer, Director
  • ELIUD HERNANDEZExecutive Officer
  • ARTURO GONZALEZDirector
  • HUMBERTO GUZMANDirector
Offering amount
$882K
Amount sold
$882K
First sale
Feb 2021
Incorporated
Corporation, Puerto Rico
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$325KraisedAug 2026 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • CARLOS A DOMINGUEZExecutive Officer
  • JOSE F RODRIGUEZ-ORENGOExecutive Officer, Director
  • SURANGANIE DHARMAWARDHANEExecutive Officer
  • FEDERICO GOODSAIDExecutive Officer, Director
  • CORNELIS VLAARExecutive Officer, Director
  • ELIUD HERNANDEZExecutive Officer
  • ARTURO GONZALEZDirector
  • HUMBERTO GUZMANDirector
Offering amount
$325K
Amount sold
$325K
First sale
Mar 2022
Incorporated
Corporation, Puerto Rico
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedAug 2026 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • CARLOS A DOMINGUEZExecutive Officer
  • JOSE F RODRIGUEZ-ORENGOExecutive Officer, Director
  • SURANGANIE DHARMAWARDHANEExecutive Officer
  • FEDERICO GOODSAIDDirector
  • CORNELIS VLAARDirector
  • ARTURO GONZALEZDirector
  • HUMBERTO GUZMANDirector
Offering amount
$500K
Amount sold
$500K
First sale
Aug 2023
Incorporated
Corporation, Puerto Rico
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$991KraisedAug 2026 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • CARLOS A DOMINGUEZExecutive Officer, Director
  • JOSE F RODRIGUEZ-ORENGOExecutive Officer, Director
  • SURANGANIE DHARMAWARDHANEExecutive Officer
  • ARTURO GONZALEZDirector
  • NEIL SANKARExecutive Officer
Amount sold
$991K
First sale
May 2026
Incorporated
Corporation, Puerto Rico
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Companies competing with MBQ Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does MBQ Pharma do?
MBQ Pharma develops precision therapeutics that target Rac and CDC42 GTPases for cancer, autoimmune, and fibrotic diseases, with a lead compound (MBQ-167) aimed at preventing and removing metastases. Its lead candidate is in a Phase 1 study, based on IP licensed from the University of Puerto Rico.
Who founded MBQ Pharma?
MBQ Pharma was founded by SURANGANIE DHARMAWARDHANE, CORNELIS VLAAR.
How much funding has MBQ Pharma raised?
MBQ Pharma has disclosed $4.2M raised across 5 rounds.
Where is MBQ Pharma headquartered?
MBQ Pharma is headquartered in San Juan, US.